

Table S2: Risk predictors within risk assessment tools compared in the studies included in the review ('x': inclusion of predictor data, '-' : absence of predictor data).^a

Risk assessment tool	Age	Age of menarche	Age of 1st live birth/ FTP	Age of menopause	Parity	Number of FTP	Menopausal status	HRT use	Oral contraceptive use	Breast density	Hysterectomy	BMI or weight	Height	Race and/ or ethnicity	Prior/ no. of breast biopsies	Other pathology	ADH	LCIS	History/ no. of degree relatives assessed	Age of onset of breast cancer	Bilateral breast cancer	Male breast cancer	Ovarian cancer (personal/ familial)	Alcohol intake	Smoking status	Time spent breastfeeding	HRT type/ duration of use	BRCA1/ BRCA2 status	Polygenic SNP score	Study ID
AABCS	x	x	x												x				1 st										Chay et al 2012 [32]	
AABCS	x	x	x												x				1 st										Min et al 2014 [36]	
BCRAT v1	x (>35 years)	x	x												x				1 st										Arrospide et al 2013 [33]	
BCRAT v2	x (>35 years)	x	x													x			1 st										Chay et al 2012 [32]	
BCRAT v2	x (>35 years)	x	x												x				1 st										Min et al 2014 [36]	
BCRAT v2-3	x (>35 years)	x	x												-				1 st										Powell et al 2014 [30]	
BCRAT v3	x (>35 years)	x	x												x	x			1 st										Choudhury et al 2020 (PLCO) [35]	
BCRAT v3	x (>35 years)	x	x												-	-			1 st										Hüsing et al 2020 [37]	
BCRAT v3 recalibrated	x (>35 years)	x	x												-	-			1 st										Hüsing et al 2020	
BCRAT v4	x (>35 years)	x	x												x	x	-		1 st										Jantzen et al 2021 [39]	
BCRAT v4	x (>35 years)	x	x												x	x	x		1 st										McCarthy et al 2020 [38]	
BCRAT v4	x (>35 years)	x	x												x	x	-		1 st										Terry et al 2019 [31]	
BCRmod	x	x	x		x			x										1 st			x									Hüsing et al 2020 [29]
BCRmod recalibrated	x	x	x		x			x										1 st			x									Hüsing et al 2020

Risk assessment tool	Age	Age of menarche	Age of 1st live birth/ FTP	Age of menopause	Parity	Number of FTP	Menopausal status	HRT use	Oral contraceptive use	Breast density	Hysterectomy	BMI or weight	Height	Race and/or ethnicity	Prior/ no. of breast biopsies	Other pathology	ADH	LCIS	History/ no. of degree relatives assessed	Age of onset of breast cancer	Bilateral breast cancer	Male breast cancer	Ovarian cancer (personal/familial)	Alcohol intake	Smoking status	Time spent breastfeeding	HRT type/ duration of use	BRCA1/ BRCA2 status	Polygenic SNP score	Study ID	
BOADICEA v3	x											x	x					1 st 2 nd 3 rd	x	x	x	x				x		Terry et al 2019 [31]			
BRCAPRO v2.1-4	x											x	-				-	Any	x	x	x	x	x			-		McCarthy et al 2020 [38]			
BRCAPRO v NR	x																x	1 st 2 nd 3 rd	x	x	x	x	x					Powell et al 2014 [30]			
BRCAPRO v2.1-3	x											x	x				-	1 st 2 nd 3 rd	x	x	x	x	x			x		Terry et al 2019 [31]			
Chen v1	x	x							x	x			x					1 st										Arrospide et al 2013 [33]			
ER+	x	x	x	x	x	x			x	x												x	x	x	x	x					Li et al 2018 [41]
ER-	x	x	x	x	x	x			x	x												x	x	x	x	x					Li et al 2018
i-CARE-Lit (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			1 st				x			x			Choudhury et al 2020 (GS) [35]			
i-CARE-Lit (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			1 st				x			-			Choudhury et al 2020 (PLCO) [35]			
i-CARE-Lit (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	-				1 st			x			-			Hurson et al 2021 (UK Biobank) [29]				
i-CARE-Lit (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			1 st			x			-			Hurson et al 2021 (WGHS)				
i-CARE-Lit + PRS (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	-				1 st			x			-	x			Hurson et al 2021 (UK Biobank)			
i-CARE-Lit + PRS (≥ 50)	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			1 st			x			-	x			Hurson et al 2021 (WGHS)			

Risk assessment tool	Age	Age of menarche	Age of 1st live birth/ FTP	Age of menopause	Parity	Number of FTP	Menopausal status	HRT use	Oral contraceptive use	Breast density	Hysterectomy	BMI or weight	Height	Race and/or ethnicity	Prior/ no. of breast biopsies	Other pathology	ADH	LCIS	History/ no. of degree relatives assessed	Age of onset of breast cancer	Bilateral breast cancer	Male breast cancer	Ovarian cancer (personal/familial)	Alcohol intake	Smoking status	Time spent breastfeeding	HRT type/ duration of use	BRCA1/ BRCA2 status	Polygenic SNP score	Study ID
i-CARE-BPC3 (≥ 50)	x x	x x	x x	x	x	x x			x									1 st				x							Choudhury et al 2020 (GS) [35]	
i-CARE-BPC3 (≥ 50)	x x	x x	x x	x	x x				x									1 st				x							Hurson et al 2021 (UK Biobank) [29]	
i-CARE-BPC3 + PRS (≥ 50)	x x	x x	x x	x	x x				x									1 st				x						x	Hurson et al 2021 (UK Biobank)	
KREA	x x	x x	x x	x		x x			x x		x		x					1 st				x							Jee et al 2020 [40]	
KRKR	x x	x x	x x	x		x x			x x		x		x					1 st				x							Jee et al 2020	
Korean (original)	x		x			x			x		x		x					1 st 2 nd						x					Min et al 2014 [36]	
Korean (updated)	x		x			x			x		x		x					1 st 2 nd						x					Min et al 2014	
TC v7	x x	x x	x x	x		x			x	x	x x	x x	x x					1 st 2 nd 3 rd				x							McCarthy et al 2020 [38]	
TC v7.02	x x	x x	x x	x	x	x			x x	x x	x x	x	x					1 st 2 nd			-	-							Brentnall et al 2018 [34]	
TC v7.02 + BD	x x	x x	x x	x	x	x			x x	x x	x x	x	x					1 st 2 nd			-	-							Brentnall et al 2018	
TC v8	x x	x x	x x	x	x	x x			x x	-	-	-	-					1 st				-							Choudhury et al 2020 (GS)	

Risk assessment tool	Age	Age of menarche	Age of 1st live birth/ FTP	Age of menopause	Parity	Number of FTP	Menopausal status	HRT use	Oral contraceptive use	Breast density	Hysterectomy	BMI or weight	Height	Race and/or ethnicity	Prior/ no. of breast biopsies	Other pathology	ADH	LCIS	History/ no. of degree relatives assessed	Age of onset of breast cancer	Bilateral breast cancer	Male breast cancer	Ovarian cancer (personal/familial)	Alcohol intake	Smoking status	Time spent breastfeeding	HRT type/ duration of use	BRCA1/ BRCA2 status	Polygenic SNP score	Study ID
TC v8	x x	x x	x x	x	x x				x x				x	x x	x	1 st 2 nd					x		x	x	x	x	Jantzen et al 2021 (CC) [39]			
TC v8.0b	x x	x x	x x	x -	- x	- x	- -	- -	- x	x -	x x	x -	x x	x -	x -	1 st 2 nd 3 rd	-			x		x	x	x	x	- -	McCarthy et al 2020 [38]			
TC v8.0b	x x	x -	x -	x -	x x	- -	x x	- -	- -	- x	x -	x -	x -	x -	x -	1 st 2 nd	x								- x	Terry et al 2019 [31]				

^a Empty cells indicate predictor not included in tool.

Abbreviations: AABCS = Asian American Breast Cancer Study; ADH = atypical ductal hyperplasia; BCRAT = Breast Cancer Risk Assessment Tool; BCRmod = Breast Cancer Risk tool including modifiable variables; BD = breast density; BMI = body mass index; BOADICEA = Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model; BRCA1 probability model; ER+ = Estrogen receptor positive model ; ER- = Estrogen receptor negative model; FTP = full term pregnancy; HRT = hormone replacement therapy; i-CARE- Lit = Individualized Coherent Absolute Risk Estimation-Literature model; i-CARE- BPC3 = Individualized Coherent Absolute Risk Estimation-Breast and Prostate Cancer Consortium model; KREA = recalibrated Korean-European model; KRKR = Korean-based model; LCIS = lobular carcinoma in situ; NR = not reported; PRS = polygenic risk score; TC = Tyrer Cuzick model; v = version.